Education
About Us
Working with TipRanks
Follow Us
Abeona Therapeutics Inc (ABEO)
:ABEO
ABEO Analyst Ratings
Strong Buy
3 Buy
0 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
ABEO Stock 12 Month Forecast
Average Price Target
$23.75
▲(389.69% Upside)
| Highest Price Target$27.50 | Average Price Target$23.75 | Lowest Price Target$20.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
H.C. Wainwright
$20
Buy
312.37%
Upside
Reiterated
12/12/25
Abeona Therapeutics: Promising Growth with ZEVASKYN's Market Expansion and Strategic AdvancementsValuation and Risks. We ascribe a total risk-adjusted net present value (rNPV) of ~$1B to Abeona's lead product a total firm value of $1.2B. This drives a price objective of $20 based on ~60M shares outstanding as of end-3Q26. We apply a 12% discount rate. Risks include, but are not limited to: (1) slower than projected uptake for pz-cel in the United States upon market introduction; (2) inability to optimize the value of pz-cel ex-U.S.; (3) setbacks with earlier-stage pipeline programs; and (4) possible long-term dilution risk.
Stifel Nicolaus
―
Buy
―
Reiterated
12/11/25
Abeona Therapeutics' Strategic Advancements and Growing Demand Justify Buy RatingWe believe the selection of UTMB as the fourth QTC activated for Zevaskyn administration aligns with mid-November management guidance (i.e. 5-7 QTCs collectively activated within <6 months) and provides the additional throughput necessary to treat a growing number of treatment-eligible patients. We view management’s announcement earlier this week re: the first Zevaskyn patient treatment occurring at the Stanford QTC (which our diligence suggests has the highest patient throughput capacity of all QTCs activated to date) represents an important milestone for the company.
Alliance Global Partners
$27.5
Buy
467.01%
Upside
Reiterated
11/13/25
Oppenheimer
$19→$20
Buy
312.37%
Upside
Reiterated
08/14/25
Unknown Analyst
Roth MKMNot Ranked
Roth MKM
$19
Buy
291.75%
Upside
Reiterated
04/30/25
Reiterating our Outperform rating and increasing PT to $19 off de-risking regulatory milestone.
LifeSci Capital
$16
Buy
229.90%
Upside
Reiterated
03/20/25
Analyst Type
Any
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
H.C. Wainwright
$20
Buy
312.37%
Upside
Reiterated
12/12/25
Abeona Therapeutics: Promising Growth with ZEVASKYN's Market Expansion and Strategic AdvancementsValuation and Risks. We ascribe a total risk-adjusted net present value (rNPV) of ~$1B to Abeona's lead product a total firm value of $1.2B. This drives a price objective of $20 based on ~60M shares outstanding as of end-3Q26. We apply a 12% discount rate. Risks include, but are not limited to: (1) slower than projected uptake for pz-cel in the United States upon market introduction; (2) inability to optimize the value of pz-cel ex-U.S.; (3) setbacks with earlier-stage pipeline programs; and (4) possible long-term dilution risk.
Stifel Nicolaus
―
Buy
―
Reiterated
12/11/25
Abeona Therapeutics' Strategic Advancements and Growing Demand Justify Buy RatingWe believe the selection of UTMB as the fourth QTC activated for Zevaskyn administration aligns with mid-November management guidance (i.e. 5-7 QTCs collectively activated within <6 months) and provides the additional throughput necessary to treat a growing number of treatment-eligible patients. We view management’s announcement earlier this week re: the first Zevaskyn patient treatment occurring at the Stanford QTC (which our diligence suggests has the highest patient throughput capacity of all QTCs activated to date) represents an important milestone for the company.
Alliance Global Partners
$27.5
Buy
467.01%
Upside
Reiterated
11/13/25
Oppenheimer
$19→$20
Buy
312.37%
Upside
Reiterated
08/14/25
Unknown Analyst
Roth MKMNot Ranked
Roth MKM
$19
Buy
291.75%
Upside
Reiterated
04/30/25
Reiterating our Outperform rating and increasing PT to $19 off de-risking regulatory milestone.
LifeSci Capital
$16
Buy
229.90%
Upside
Reiterated
03/20/25
Best Analysts Covering Abeona Therapeutics
1 Month
xxx
Success Rate
4/5 ratings generated profit
Average Return
+5.70%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 80.00% of your transactions generating a profit, with an average return of +5.70% per trade.
3 Months
xxx
Success Rate
3/5 ratings generated profit
Average Return
-2.64%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 60.00% of your transactions generating a profit, with an average return of -2.64% per trade.
1 Year
Success Rate
2/5 ratings generated profit
Average Return
+0.30%
reiterated a buy rating last month
Copying James Molloy's trades and holding each position for 1 Year would result in 40.00% of your transactions generating a profit, with an average return of +0.30% per trade.
2 Years
xxx
Success Rate
3/5 ratings generated profit
Average Return
+16.00%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 60.00% of your transactions generating a profit, with an average return of +16.00% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
ABEO Analyst Recommendation Trends
Rating
Aug 25
Sep 25
Oct 25
Nov 25
Dec 25
Strong Buy
4
4
4
5
5
Buy
0
0
0
0
1
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
4
4
4
5
6
Each month's total comprises the sum of three months' worth of ratings.
ABEO Financial Forecast
ABEO Stock Forecast FAQ
What is ABEO’s average 12-month price target, according to analysts?
Based on analyst ratings, Abeona Therapeutics Inc’s 12-month average price target is 23.75.
What is ABEO’s upside potential, based on the analysts’ average price target?
Abeona Therapeutics Inc has 389.69% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is ABEO a Buy, Sell or Hold?
Abeona Therapeutics Inc has a consensus rating of Strong Buy which is based on 3 buy ratings, 0 hold ratings and 0 sell ratings.
What is Abeona Therapeutics Inc’s price target?
The average price target for Abeona Therapeutics Inc is 23.75. This is based on 3 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $27.50 ,the lowest forecast is $20.00. The average price target represents 389.69% Increase from the current price of $4.85.
The highest analyst price target is $27.50 ,the lowest forecast is $20.00. The average price target represents 389.69% Increase from the current price of $4.85.
What do analysts say about Abeona Therapeutics Inc?
Abeona Therapeutics Inc’s analyst rating consensus is a Strong Buy. This is based on the ratings of 3 Wall Streets Analysts.
How can I buy shares of ABEO?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.